ERBB2 and breast cancer: In tests with breast cancer cell lines, the Oslo-2 mAb had a strong reactivity to p95HER2-T47D but did not bind to the HER2 positive SK-BR-3 and MDA-MB-468 lines, or to the HER2 negative T47D, MCF7 and MDA-MB-231 cell lines (Figure 2).